Difference between revisions of "Alisertib (MLN-8237)"
Jump to navigation
Jump to search
m |
m |
||
| Line 4: | Line 4: | ||
=Preliminary results= | =Preliminary results= | ||
| − | |||
==[[Mantle cell lymphoma]]== | ==[[Mantle cell lymphoma]]== | ||
| Line 17: | Line 16: | ||
[[Category:Aurora kinase inhibitors]] | [[Category:Aurora kinase inhibitors]] | ||
| − | |||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
Revision as of 01:47, 1 January 2016
Mechanism of action
Aurora A kinase (AAK) inhibitor
Preliminary results
Mantle cell lymphoma
- Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014 Jan 1;32(1):44-50. Epub 2013 Sep 16. link to original article PubMed
Peripheral T-cell lymphoma
- Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, Friedberg JW. Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol. 2015 Jul 20;33(21):2399-404. Epub 2015 Jun 15. link to original article PubMed